{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:28:56Z","timestamp":1793694536045,"version":"4.5.1"},"reference-count":234,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2026-BS-0570"],"award-info":[{"award-number":["2026-BS-0570"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013099","name":"Scientific Research Fund of Liaoning Provincial Education Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.phrs.2026.108456","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:44:08Z","timestamp":1789688648000},"page":"108456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological intersections between type 2 diabetes and cancer: Metabolic crosstalk, antidiabetic therapies and clinical implications"],"prefix":"10.1016","volume":"233","author":[{"given":"Dequan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lddd.2025.100204","article-title":"Regulation of hyperglycemia in type 2 diabetes mellitus: insights into current therapeutic pathways","volume":"22","author":"Rahu","year":"2025","journal-title":"Lett. Drug. Des. Discov."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/0109298665340227241115110404","article-title":"Identifying the role of individual seal iapp amino acids in inhibiting the aggregation of human IAPP","volume":"32","author":"Menefee","year":"2024","journal-title":"Protein Pept. Lett."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.lddd.2025.100226","article-title":"Exploring the therapeutic potential of phytocompounds from selected medicinal plants for type2 diabetes mellitus management through computational analysis","volume":"22","author":"Sulthana","year":"2025","journal-title":"Lett. Drug. Des. Discov."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.curpro.2025.100014","article-title":"Incretin hormones: mechanisms, therapeutic implications, and future directions in glucose regulation and diabetes management","volume":"22","author":"Zargar","year":"2025","journal-title":"Curr. Proteom."},{"issue":"10365","key":"10.1016\/j.phrs.2026.108456_bib5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"issue":"10397","key":"10.1016\/j.phrs.2026.108456_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108456_bib7","doi-asserted-by":"crossref","first-page":"g7607","DOI":"10.1136\/bmj.g7607","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.phrs.2026.108456_bib8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.2337\/dc20-0204","article-title":"Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people","volume":"43","author":"Ling","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-8587(24)00346-2","article-title":"Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials","volume":"13","author":"Kanbour","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib10","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1055-9965.EPI-06-0410","article-title":"A meta-analysis of diabetes mellitus and the risk of prostate cancer","volume":"15","author":"Kasper","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"23","key":"10.1016\/j.phrs.2026.108456_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16234010","article-title":"Diabetes Mellitus and Prostate Cancer Risk-A Systematic Review and Meta-Analysis","volume":"16","author":"Drab","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41416-020-0910-y","article-title":"The association of diabetes with risk of prostate cancer defined by clinical and molecular features","volume":"123","author":"Feng","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib13","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1210\/jc.2019-01142","article-title":"Neither hormonal factors nor ages explain lower prostate cancer risk in older men with diabetes mellitus","volume":"104","author":"Chan","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2026.108456_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/obr.12282","article-title":"Testosterone and obesity","volume":"16","author":"Kelly","year":"2015","journal-title":"Obes. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10552-018-1067-3","article-title":"The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer","volume":"29","author":"Miller","year":"2018","journal-title":"Cancer Causes & Control."},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10552-020-01347-4","article-title":"Examining the relationship between diabetes and prostate cancer through changes in screening guidelines","volume":"31","author":"Miller","year":"2020","journal-title":"Cancer Causes & Control."},{"issue":"8","key":"10.1016\/j.phrs.2026.108456_bib18","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/ijc.31587","article-title":"Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus","volume":"143","author":"H\u00e4ggstr\u00f6m","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.euf.2018.04.001","article-title":"Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology","volume":"5","author":"Campi","year":"2018","journal-title":"Eur. Urol. Focus."},{"issue":"ement_1","key":"10.1016\/j.phrs.2026.108456_bib20","first-page":"S183","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142026","volume":"49","author":"Bajaj","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4093\/dmj.2020.0250","article-title":"Hyperinsulinemia in Obesity, Inflammation, and Cancer","volume":"45","author":"Zhang","year":"2021","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.phrs.2026.108456_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116450","article-title":"Hyperglycemia-driven signaling bridges between diabetes and cancer","volume":"229","author":"Ghareghomi","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib23","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1530\/ERC-11-0374","article-title":"Obesity, type 2 diabetes, and cancer: the insulin and IGF connection","volume":"19","author":"Cohen","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.phrs.2026.108456_bib24","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399411002109","article-title":"PI3K\/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis","volume":"14","author":"Schultze","year":"2012","journal-title":"Expert. Rev. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108456_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122244","article-title":"Network based approach to identify interactions between Type 2 diabetes and cancer comorbidities","volume":"335","author":"Nayan","year":"2023","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149822","article-title":"The activation of ERK1\/2 and JNK MAPK signaling by Insulin\/IGF-1 is responsible for the development of colon cancer with type 2 diabetes mellitus","volume":"11","author":"Teng","year":"2016","journal-title":"PLoS. One"},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079708","article-title":"Hyperglycemia enhances the proliferation of non-tumorigenic and malignant mammary epithelial cells through increased leptin\/IGF1R signaling and activation of AKT\/mTOR","volume":"8","author":"Lopez","year":"2013","journal-title":"PLoS. One"},{"issue":"36","key":"10.1016\/j.phrs.2026.108456_bib28","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1021\/acs.biochem.5b00805","article-title":"Structural dynamics of insulin receptor and transmembrane signaling","volume":"54","author":"Tatulian","year":"2015","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/0113892029298721240627095839","article-title":"Gene-knockdown Methods for silencing nuclear-localized insulin receptors in lung adenocarcinoma cells: a bioinformatics approach","volume":"26","author":"Ren","year":"2024","journal-title":"Curr. Genom."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib30","doi-asserted-by":"crossref","first-page":"a008946","DOI":"10.1101\/cshperspect.a008946","article-title":"The insulin receptor: both a prototypical and atypical receptor tyrosine kinase","volume":"5","author":"Hubbard","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cimb46010041","article-title":"Phosphorylation codes in IRS-1 and IRS-2 are associated with the activation\/inhibition of insulin canonical signaling pathways","volume":"46","author":"Mart\u00ednez B\u00e1ez","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","article-title":"Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy","volume":"7","author":"Zhao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/ijms22041743","article-title":"The Role of mTOR Signaling as a Therapeutic Target in Cancer","volume":"22","author":"Popova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108456_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib35","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer","volume":"27","author":"Narayan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.phrs.2026.108456_bib36","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-24-0967","article-title":"PI3K Inhibitors in Hematology: When One Door Closes\u2026","volume":"30","author":"Sk\u00e5nland","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-5793(94)80346-3","article-title":"The GRB2\/Sem-5 adaptor protein","volume":"338","author":"Downward","year":"1994","journal-title":"FEBS Lett."},{"issue":"5116","key":"10.1016\/j.phrs.2026.108456_bib38","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1126\/science.8316835","article-title":"The function of GRB2 in linking the insulin receptor to Ras signaling pathways","volume":"260","author":"Skolnik","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108456_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.tem.2010.06.007","article-title":"The proliferating role of insulin and insulin-like growth factors in cancer","volume":"21","author":"Gallagher","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384101.2022.2108117","article-title":"Cell cycle control by the insulin-like growth factor signal: at the crossroad between cell growth and mitotic regulation","volume":"22","author":"Scalia","year":"2023","journal-title":"Cell. Cycle"},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib42","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MED.0b013e32833bf6dc","article-title":"Role of IL-1beta in type 2 diabetes","volume":"17","author":"Dinarello","year":"2010","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00592-017-1039-1","article-title":"Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile","volume":"54","author":"Cimini","year":"2017","journal-title":"Acta Diabetol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10787-018-0458-0","article-title":"IL-6 signalling pathways and the development of type 2 diabetes","volume":"26","author":"Akbari","year":"2018","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.phrs.2026.108456_bib46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0083-6729(08)00621-3","article-title":"Chapter 21 Interleukin-6 and Insulin Resistance","volume":"80","author":"Kim","year":"2009","journal-title":"Vitam. Horm."},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib47","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/carcin\/bgab075","article-title":"JAK\/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance","volume":"42","author":"Sabaawy","year":"2021","journal-title":"Carcinogenesis"},{"issue":"8","key":"10.1016\/j.phrs.2026.108456_bib48","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.7150\/ijbs.89942","article-title":"The PI3K\/Akt pathway and glucose metabolism: a dangerous liaison in cancer","volume":"20","author":"Fontana","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1042\/BST20140070","article-title":"PI3K\/Akt-mediated regulation of p53 in cancer","volume":"42","author":"Abraham","year":"2014","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2026.108456_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2025.101420","article-title":"Cross-talk between cancer and diabetes: Exploring shared molecular pathways in cellular metabolism and signaling","volume":"106","author":"Tang","year":"2025","journal-title":"Mol. Asp. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.115024","article-title":"Skeletal muscle metabolism in health and disease: Mechanisms, interventions, and clinical perspectives","volume":"29","author":"Lin","year":"2026","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib53","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/JOE-16-0598","article-title":"Skeletal muscle insulin resistance: role of mitochondria and other ROS sources","volume":"233","author":"Di Meo","year":"2017","journal-title":"J. Endocrinol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5483\/BMBRep.2023-0064","article-title":"The role of myokines in cancer: crosstalk between skeletal muscle and tumor","volume":"56","author":"Park","year":"2023","journal-title":"BMB Rep."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib55","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1042\/BST20221066","article-title":"Insulin signalling and GLUT4 trafficking in insulin resistance","volume":"51","author":"van Gerwen","year":"2023","journal-title":"Biochem. Soc. Trans."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib56","doi-asserted-by":"crossref","first-page":"C879","DOI":"10.1152\/ajpcell.00069.2014","article-title":"Signal transduction meets vesicle traffic: the software and hardware of GLUT4 translocation","volume":"306","author":"Klip","year":"2014","journal-title":"Am. J. Physiol. -Cell. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib57","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmet.2021.03.020","article-title":"The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia","volume":"33","author":"Sylow","year":"2021","journal-title":"Cell. Metab."},{"issue":"27","key":"10.1016\/j.phrs.2026.108456_bib58","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1038\/onc.2011.495","article-title":"Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia","volume":"31","author":"Gallagher","year":"2011","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3089","article-title":"Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes","volume":"14","author":"Ferguson","year":"2012","journal-title":"Breast Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib60","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.3390\/ijms19103267","article-title":"mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression","volume":"19","author":"Harachi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib61","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1096\/fj.201700442R","article-title":"AMPK in skeletal muscle function and metabolism","volume":"32","author":"Kj\u00f8bsted","year":"2017","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mce.2012.06.019","article-title":"AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: Implications for obesity","volume":"366","author":"O\u2019Neill","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib63","doi-asserted-by":"crossref","first-page":"C1011","DOI":"10.1152\/ajpcell.00157.2020","article-title":"Impaired glucose partitioning in primary myotubes from severely obese women with type 2 diabetes","volume":"319","author":"Zou","year":"2020","journal-title":"Am. J. Physiol. -Cell. Physiol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib64","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029793","article-title":"Skeletal muscle as an endocrine organ: the role of myokines in exercise adaptations","volume":"7","author":"Hoffmann","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3803\/EnM.2015.30.3.235","article-title":"Connecting Myokines and Metabolism","volume":"30","author":"Ahima","year":"2015","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2026.108456_bib66","article-title":"Role of irisin in physiology and pathology","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011310","article-title":"Hyperglycemia induces an immunosuppressive microenvironment in colorectal cancer liver metastases by recruiting peripheral blood monocytes through the CCL3-CCR1 axis","volume":"13","author":"Peng","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib68","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/metabo15010059","article-title":"Exerkines and sarcopenia: unveiling the mechanism behind exercise-induced mitochondrial homeostasis","volume":"15","author":"Wang","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.phrs.2026.108456_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.1052608","article-title":"Exercise alleviates diabetic complications by inhibiting oxidative stress-mediated signaling cascade and mitochondrial metabolic stress in GK diabetic rat tissues","volume":"13","author":"John","year":"2022","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1249\/MSS.0000000000002783","article-title":"Myokine expression and tumor-suppressive effect of serum after 12 wk of exercise in prostate cancer patients on ADT","volume":"54","author":"KIM","year":"2021","journal-title":"Med. Sci. Sports & Exerc."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jesf.2023.11.002","article-title":"Acute effect of exercise intensity on circulating FGF-21, FSTL-1, cathepsin B, and BDNF in young men","volume":"22","author":"Ji","year":"2023","journal-title":"J. Exerc. Sci. & Fit."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib72","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.apsb.2023.01.012","article-title":"Pathophysiology of obesity and its associated diseases","volume":"13","author":"Jin","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2026.108456_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.685923","article-title":"Targeting Adipokines in Obesity-Related Tumors","volume":"11","author":"Pu","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib74","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41574-021-00487-0","article-title":"Metabolic pathways in obesity-related breast cancer","volume":"17","author":"Brown","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib75","first-page":"8","article-title":"Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link","volume":"5","author":"Abdulla","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13058-015-0622-z","article-title":"Leptin produced by obese adipose stromal\/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers","volume":"17","author":"Strong","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"22","key":"10.1016\/j.phrs.2026.108456_bib77","doi-asserted-by":"crossref","first-page":"32306","DOI":"10.18632\/oncotarget.8615","article-title":"Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib78","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3390\/ijms20102519","article-title":"Adiponectin, Obesity, and Cancer: Clash of the Bigwigs in Health and Disease","volume":"20","author":"Parida","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.phrs.2026.108456_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235912","article-title":"Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy","volume":"13","author":"Luby","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108456_bib80","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.freeradbiomed.2016.12.025","article-title":"4-Hydroxynonenal metabolites and adducts in pre-carcinogenic conditions and cancer","volume":"111","author":"Gu\u00e9raud","year":"2017","journal-title":"Free. Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043520","article-title":"7,8-Dihydroxyflavone attenuates inflammatory response and insulin resistance induced by the paracrine interaction between adipocytes and macrophages","volume":"24","author":"Shin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108456_bib82","article-title":"Effect of natural polyphenols in Chinese herbal medicine on obesity and diabetes: Interactions among gut microbiota, metabolism, and immunity","volume":"9","author":"Chen","year":"2022","journal-title":"Front. Nutr."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib83","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1474-9726.2010.00608.x","article-title":"Fat tissue, aging, and cellular senescence","volume":"9","author":"Tchkonia","year":"2010","journal-title":"Aging Cell."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41574-018-0126-x","article-title":"The obese adipose tissue microenvironment in cancer development and progression","volume":"15","author":"Quail","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/biology11020339","article-title":"The Impact of Obesity, Adipose Tissue, and Tumor Microenvironment on Macrophage Polarization and Metastasis","volume":"11","author":"Habanjar","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.phrs.2026.108456_bib86","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8803404","article-title":"Mitochondrial Stress in Metabolic Inflammation: Modest Benefits and Full Losses","volume":"2022","author":"Yuan","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2026.108456_bib87","article-title":"Effect of mind-body exercise on risk factors for metabolic syndrome including insulin resistance: a meta-analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib88","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz054","article-title":"Intentional Weight Loss and Obesity-Related Cancer Risk","volume":"3","author":"Luo","year":"2019","journal-title":"JNCI Cancer Spectr."},{"issue":"24","key":"10.1016\/j.phrs.2026.108456_bib89","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of bariatric surgery with cancer risk and mortality in adults with obesity","volume":"327","author":"Aminian","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib90","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/obr.12281","article-title":"The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise","volume":"16","author":"Schmidt","year":"2015","journal-title":"Obes. Rev."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib91","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. & Hepatol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib92","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/cancers12071849","article-title":"The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective","volume":"12","author":"Brocco","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib93","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.3233\/THC-231331","article-title":"Risk factors of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"32","author":"Yin","year":"2024","journal-title":"Technol. Health Care"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib94","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2174\/0115665232308821240826075513","article-title":"Proteogenomic Identification and Analysis of KIF5B as a PrognosticSignature for Hepatocellular Carcinoma","volume":"25","author":"Qi","year":"2024","journal-title":"Curr. Gene Ther."},{"issue":"9","key":"10.1016\/j.phrs.2026.108456_bib95","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell. Death Dis."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib96","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4161\/cc.20259","article-title":"The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease","volume":"11","author":"Daugherity","year":"2012","journal-title":"Cell. Cycle"},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib97","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The Role of Cholesterol in the Pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib98","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis: An Overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib99","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1152\/physiol.00048.2018","article-title":"Hepatic Insulin Clearance: Mechanism and Physiology","volume":"34","author":"Najjar","year":"2019","journal-title":"Physiology"},{"key":"10.1016\/j.phrs.2026.108456_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1454161","article-title":"The role of metabolic reprogramming in liver cancer and its clinical perspectives","volume":"14","author":"Lu","year":"2024","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib101","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.25600","article-title":"V-AKT murine thymoma viral oncogene homolog\/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis","volume":"55","author":"Evert","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108456_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111378","article-title":"Cancer-associated fibroblasts promote the progression and chemoresistance of HCC by inducing IGF-1","volume":"124","author":"Lv","year":"2024","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib103","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.molcel.2012.11.022","article-title":"Glucose-Induced \u03b2-Catenin Acetylation Enhances Wnt Signaling in Cancer","volume":"49","author":"Chocarro-Calvo","year":"2012","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/srep27558","article-title":"Glucose induced activation of canonical Wnt signaling pathway in hepatocellular carcinoma is regulated by DKK4","volume":"6","author":"Chouhan","year":"2016","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib105","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.2948","article-title":"Diabetes, weight change, and pancreatic cancer risk","volume":"6","author":"Yuan","year":"2020","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib106","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1940-6207.CAPR-23-0162","article-title":"Protein advanced glycation end products and their implications in pancreatic cancer","volume":"16","author":"Senavirathna","year":"2023","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib107","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/cdd.2009.149","article-title":"The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival","volume":"17","author":"Kang","year":"2009","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.phrs.2026.108456_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108689","article-title":"Differential gut microbiota composition between type 2 diabetes mellitus patients and healthy controls: a systematic review","volume":"173","author":"Umirah","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"issue":"35","key":"10.1016\/j.phrs.2026.108456_bib111","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2016.67.9712","article-title":"Obesity and Cancer Mechanisms: Cancer Metabolism","volume":"34","author":"Hopkins","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib112","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.3390\/ijms19113615","article-title":"Insulin Receptor Isoforms in Cancer","volume":"19","author":"Vella","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40170-022-00282-z","article-title":"Effects of hyperinsulinemia on pancreatic cancer development and the immune microenvironment revealed through single-cell transcriptomics","volume":"10","author":"Zhang","year":"2022","journal-title":"Cancer Metab."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib114","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/db09-1291","article-title":"Insulin-Sensitizing Therapy Attenuates Type 2 Diabetes\u2013Mediated Mammary Tumor Progression","volume":"59","author":"Fierz","year":"2009","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tem.2011.09.005","article-title":"Sex hormone-binding globulin and type 2 diabetes mellitus","volume":"23","author":"Le","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib116","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1677\/joe.0.124R001","article-title":"Effect of insulin-like growth factor-type i (igf-i) and insulin on the secretion of sex hormone binding globulin and igf-i binding protein (ibp-i) by human hepatoma cells","volume":"124","author":"Singh","year":"1990","journal-title":"J. Endocrinol."},{"issue":"34","key":"10.1016\/j.phrs.2026.108456_bib117","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030299","article-title":"Diabetes mellitus and endometrial carcinoma: risk factors and etiological links","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine"},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib118","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMoa0804381","article-title":"Sex Hormone\u2013Binding Globulin and Risk of Type 2 Diabetes in Women and Men","volume":"361","author":"Ding","year":"2009","journal-title":"New. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib119","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1158\/1055-9965.EPI-08-0734","article-title":"Identification of common variants in the shbg gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women","volume":"17","author":"Thompson","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib120","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1002\/cam4.5545","article-title":"Breast cancer risk for women with diabetes and the impact of metformin: a meta-analysis","volume":"12","author":"Lu","year":"2023","journal-title":"Cancer Med."},{"issue":"15","key":"10.1016\/j.phrs.2026.108456_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158194","article-title":"Adipose tissue dysfunction and obesity-related male hypogonadism","volume":"23","author":"Genchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib122","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jcb.20929","article-title":"Interaction of IGF signaling and the androgen receptor in prostate cancer progression","volume":"99","author":"Wu","year":"2006","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib123","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2015.07.026","article-title":"The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer","volume":"367","author":"Heidegger","year":"2015","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-003218","article-title":"Review of the direct and indirect effects of hyperglycemia on the HPA axis in T2DM and the co-occurrence of depression","volume":"12","author":"Mosili","year":"2024","journal-title":"BMJ Open. Diabetes Res. & Care"},{"key":"10.1016\/j.phrs.2026.108456_bib125","article-title":"Stress and cancer: The mechanisms of immune dysregulation and management","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2026.108456_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1416472","article-title":"Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target","volume":"12","author":"Zhao","year":"2024","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41523-021-00275-z","article-title":"Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial","volume":"7","author":"Goodwin","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-020-05621-6","article-title":"Metformin is distributed to tumor tissue in breast cancer patients in vivo: A 11C-metformin PET\/CT study","volume":"181","author":"Sundelin","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib129","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib130","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol. Metab."},{"issue":"20","key":"10.1016\/j.phrs.2026.108456_bib131","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib132","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.5547","article-title":"Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies","volume":"32","author":"Acton","year":"2022","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"issue":"9","key":"10.1016\/j.phrs.2026.108456_bib133","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/dom.13766","article-title":"Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data","volume":"21","author":"Bykov","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib134","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.therap.2018.09.074","article-title":"Interest and challenges of pharmacoepidemiology for the study of drugs used in diabetes","volume":"74","author":"Salvo","year":"2018","journal-title":"Therapies"},{"issue":"9","key":"10.1016\/j.phrs.2026.108456_bib135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pds.5083","article-title":"Dell'Aniello S. Time-related biases in pharmacoepidemiology","volume":"29","author":"Suissa","year":"2020","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib136","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/pds.5258","article-title":"New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices","volume":"30","author":"Luijken","year":"2021","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib138","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40471-017-0131-y","article-title":"Propensity Scores in Pharmacoepidemiology: Beyond the Horizon","volume":"4","author":"Jackson","year":"2017","journal-title":"Curr. Epidemiol. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib139","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/aje\/kwad189","article-title":"A Cautionary Note on Using Propensity Score Calibration to Control for Unmeasured Confounding Bias When the Surrogacy Assumption Is Absent","volume":"193","author":"Wan","year":"2023","journal-title":"Am. J. Epidemiol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108456_bib140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2188\/jea.JE20200226","article-title":"Understanding Marginal Structural Models for Time-Varying Exposures: Pitfalls and Tips","volume":"30","author":"Shinozaki","year":"2020","journal-title":"J. Epidemiol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib141","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/bimj.201600223","article-title":"Modeling time-varying exposure using inverse probability of treatment weights","volume":"60","author":"Graff\u00e9o","year":"2017","journal-title":"Biom. J."},{"issue":"9","key":"10.1016\/j.phrs.2026.108456_bib142","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib143","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and Molecular Mechanisms of Metformin Action","volume":"42","author":"LaMoia","year":"2020","journal-title":"Endocr. Rev."},{"issue":"14","key":"10.1016\/j.phrs.2026.108456_bib144","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-22-3042","article-title":"Metformin Reprograms Tryptophan Metabolism to Stimulate CD8+ T-cell Function in Colorectal Cancer","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108456_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172541","article-title":"Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1","volume":"859","author":"Xue","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib146","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.cmet.2016.09.006","article-title":"Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin","volume":"24","author":"Gui","year":"2016","journal-title":"Cell. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib147","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/bcp.15546","article-title":"Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients","volume":"89","author":"Phillips","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib148","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1038\/s41598-017-10010-z","article-title":"Results from 11C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly","volume":"7","author":"Iversen","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib149","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann. Oncol."},{"issue":"35","key":"10.1016\/j.phrs.2026.108456_bib150","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.23.00296","article-title":"Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer","volume":"41","author":"Goodwin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108456_bib151","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.breast.2019.08.003","article-title":"A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy","volume":"48","author":"Pimentel","year":"2019","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib152","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41391-022-00492-y","article-title":"A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)","volume":"25","author":"Bilusic","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib153","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clgc.2021.08.008","article-title":"TAXOMET: a french prospective multicentric randomized phase ii study of docetaxel plus metformin versus docetaxel plus placebo in metastatic castration-resistant prostate cancer","volume":"19","author":"Pujalte Martin","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib154","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","article-title":"Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09)","volume":"66","author":"Rothermundt","year":"2014","journal-title":"Eur. Urol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007235","article-title":"Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer","volume":"11","author":"Akce","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib156","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/1940-6207.CAPR-20-0580","article-title":"The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis","volume":"14","author":"Park","year":"2021","journal-title":"Cancer Prev. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib157","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-025-56914-7","article-title":"Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced\/metastatic endometrial cancer: the ENDOLA phase I\/II trial","volume":"16","author":"Piffoux","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib158","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1470-2045(15)00027-3","article-title":"Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"16","author":"Kordes","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2026.108456_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111880","article-title":"Metformin to treat breast cancer: an application of the prevalent new-user design for observational studies with no active comparator","volume":"185","author":"Khouri","year":"2025","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2026.108456_bib160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fendo.2012.00021","article-title":"Insulin analogs and cancer","volume":"3","author":"Sciacca","year":"2012","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib161","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.numecd.2018.02.010","article-title":"Long-acting insulin analogs and cancer","volume":"28","author":"Sciacca","year":"2018","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib162","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/EC-17-0358","article-title":"Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats","volume":"7","author":"Mori","year":"2018","journal-title":"Endocr. Connect."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib163","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.2337\/dc13-0263","article-title":"Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin","volume":"36","author":"St\u00fcrmer","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib164","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2337\/dc12-0506","article-title":"Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases","volume":"36","author":"Fagot","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib165","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s00125-011-2429-5","article-title":"Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database","volume":"55","author":"Blin","year":"2012","journal-title":"Diabetologia"},{"issue":"5 1","key":"10.1016\/j.phrs.2026.108456_bib166","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.metabol.2006.02.003","article-title":"The place of sulfonylureas in the therapy for type 2 diabetes mellitus","volume":"55","author":"Del Prato","year":"2006","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib167","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1634\/theoncologist.2013-0177","article-title":"Effects of sulfonylureas on tumor growth: a review of the literature","volume":"18","author":"Pasello","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2026.108456_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215611","article-title":"Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression","volume":"536","author":"Chen","year":"2022","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib169","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1753-0407.12435","article-title":"Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: a systematic review","volume":"9","author":"Chen","year":"2017","journal-title":"J. Diabetes"},{"key":"10.1016\/j.phrs.2026.108456_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172598","article-title":"Sulfonylurea derivatives and cancer, friend or foe?","volume":"861","author":"Hendriks","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib171","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.metabol.2013.01.014","article-title":"Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies","volume":"62","author":"Thakkar","year":"2013","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib172","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.2337\/dc15-1358","article-title":"The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes","volume":"38","author":"Tuccori","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2026.108456_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib174","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2026.108456_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176803","article-title":"Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies","volume":"978","author":"Naeimzadeh","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108456_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177002","article-title":"Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination","volume":"983","author":"Ren","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib177","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s40618-024-02351-0","article-title":"Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis","volume":"47","author":"Xu","year":"2024","journal-title":"J. Endocrinol. Invest."},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib178","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the Forgotten Diabetes Medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr. Diab Rep."},{"key":"10.1016\/j.phrs.2026.108456_bib179","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/845340","article-title":"Chemotherapy and chemoprevention by thiazolidinediones","volume":"2015","author":"Fr\u00f6hlich","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib180","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00535-010-0310-9","article-title":"Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs","volume":"45","author":"Okumura","year":"2010","journal-title":"J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib181","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/hep.25509","article-title":"Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus","volume":"55","author":"Chang","year":"2012","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib182","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1093\/annonc\/mdr020","article-title":"Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients","volume":"22","author":"He","year":"2011","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib183","doi-asserted-by":"crossref","first-page":"E675","DOI":"10.1503\/cmaj.112102","article-title":"Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis","volume":"184","author":"Colmers","year":"2012","journal-title":"Cmaj"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib184","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.phrs.2026.108456_bib185","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3390\/cancers13092191","article-title":"CD26\/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology","volume":"13","author":"Kawakita","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib186","doi-asserted-by":"crossref","first-page":"679","DOI":"10.15252\/emmm.201506145","article-title":"Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies","volume":"8","author":"Decalf","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108456_bib187","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ni.3201","article-title":"Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy","volume":"16","author":"da Silva","year":"2015","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib188","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","article-title":"Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth","volume":"20","author":"Hollande","year":"2019","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib189","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/0008-5472.CAN-18-0620","article-title":"Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial\u2013Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12\/CXCR4\/mTOR Axis","volume":"79","author":"Yang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108456_bib190","article-title":"Antidiabetic DPP-4 Inhibitors Reprogram Tumor Microenvironment That Facilitates Murine Breast Cancer Metastasis Through Interaction With Cancer Cells via a ROS\u2013NF-\u043aB\u2013NLRP3 Axis","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib191","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib192","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/dc15-2780","article-title":"Pancreatic Safety of Sitagliptin in the TECOS Study","volume":"40","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2026.108456_bib193","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.clinthera.2024.06.015","article-title":"Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"46","author":"Tuersun","year":"2024","journal-title":"Clin. Ther."},{"key":"10.1016\/j.phrs.2026.108456_bib194","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib195","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3390\/genes16111352","article-title":"GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways","volume":"16","author":"Lucente","year":"2025","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib196","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","article-title":"Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence","volume":"13","author":"Lin","year":"2025","journal-title":"Biomark. Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib197","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib198","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/JME-12-0186","article-title":"Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man","volume":"50","author":"Boess","year":"2013","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib199","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.phrs.2026.108456_bib200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","article-title":"GLP-1RA Use and Thyroid Cancer Risk","volume":"151","author":"Brito","year":"2025","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.phrs.2026.108456_bib201","article-title":"Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis","author":"Ko","year":"2025","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib202","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib203","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1080\/07357907.2025.2585512","article-title":"The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients","volume":"43","author":"Cuomo","year":"2025","journal-title":"Cancer Invest."},{"issue":"10","key":"10.1016\/j.phrs.2026.108456_bib204","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.phrs.2026.108456_bib205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib206","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib207","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/clinem\/dgae038","article-title":"Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)","volume":"109","author":"Frias","year":"2024","journal-title":"J. Clin. Endocrinol. & Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib208","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3803\/EnM.2024.2164","article-title":"Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis","volume":"40","author":"Kamrul-Hasan","year":"2025","journal-title":"Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102062","volume":"8","author":"Silvestris","year":"2023","journal-title":"ESMO Open."},{"issue":"12","key":"10.1016\/j.phrs.2026.108456_bib210","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s40618-024-02417-z","volume":"47","author":"Natalicchio","year":"2024","journal-title":"J. Endocrinol. Investig."},{"issue":"11","key":"10.1016\/j.phrs.2026.108456_bib211","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1245\/s10434-021-09748-8","article-title":"Association of Insulin Resistance and Higher Oncotype DX\u2122 Recurrence Score","volume":"28","author":"Gordon","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"23","key":"10.1016\/j.phrs.2026.108456_bib212","doi-asserted-by":"crossref","first-page":"13012","DOI":"10.1073\/pnas.1918845117","article-title":"Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1","volume":"117","author":"Xie","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib213","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3747\/co.20.1499","article-title":"Glucocorticoid-Induced Hyperglycemia Is Prevalent and Unpredictable for Patients Undergoing Cancer Therapy: An Observational Cohort Study","volume":"20","author":"Harris","year":"2013","journal-title":"Curr. Oncol."},{"issue":"20","key":"10.1016\/j.phrs.2026.108456_bib214","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"New. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.phrs.2026.108456_bib215","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"New. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.phrs.2026.108456_bib216","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1002\/cncr.35443","article-title":"Insulin resistance during androgen deprivation therapy in men with prostate cancer","volume":"130","author":"Basaria","year":"2024","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib217","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2013.02.023","article-title":"Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer","volume":"65","author":"Keating","year":"2013","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib218","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15053","article-title":"Hyperglycaemia following immune checkpoint inhibitor therapy\u2014Incidence, aetiology and assessment","volume":"40","author":"Mulla","year":"2023","journal-title":"Diabet. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib219","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0513","article-title":"Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer","volume":"12","author":"Percik","year":"2023","journal-title":"Endocr. Connect."},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jdiacomp.2018.12.012","article-title":"Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy","volume":"33","author":"Zylla","year":"2019","journal-title":"J. Diabetes Complicat."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib221","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jdiacomp.2016.09.006","article-title":"The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis","volume":"31","author":"Alenzi","year":"2016","journal-title":"J. Diabetes Complicat."},{"issue":"5","key":"10.1016\/j.phrs.2026.108456_bib222","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of diabetes mellitus in patients with CKD: Core Curriculum 2022","volume":"79","author":"Hahr","year":"2021","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102935","article-title":"Management of type 2 diabetes in patients with compensated liver cirrhosis: short of evidence, plenty of potential","volume":"18","author":"Arvanitakis","year":"2023","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib224","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2015","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib225","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4239\/wjd.v15.i6.1178","article-title":"Metformin-associated lactic acidosis: a mini review of pathophysiology, diagnosis and management in critically ill patients","volume":"15","author":"See","year":"2024","journal-title":"World J. Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib226","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/pancan.2018.0016","article-title":"Euglycemic diabetic ketoacidosis due to sodium\u2013glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy","volume":"4","author":"Pace","year":"2018","journal-title":"J. Pancreat. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib227","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.bja.2026.02.031","article-title":"Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"136","author":"Oprea","year":"2026","journal-title":"Br. J. Anaesth."},{"issue":"1","key":"10.1016\/j.phrs.2026.108456_bib228","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12020-025-04494-3","article-title":"Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: a systematic review and Meta-Analysis of randomized controlled trials","volume":"91","author":"Joy","year":"2026","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.phrs.2026.108456_bib229","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bja.2024.01.001","article-title":"Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration","volume":"132","author":"van Zuylen","year":"2024","journal-title":"Br. J. Anaesth."},{"issue":"2","key":"10.1016\/j.phrs.2026.108456_bib230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2026.108456_bib231","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cardfail.2008.02.007","article-title":"Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction","volume":"14","author":"Giles","year":"2008","journal-title":"J. Card. Fail."},{"issue":"16","key":"10.1016\/j.phrs.2026.108456_bib232","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3390\/cancers16162821","article-title":"Perioperative Management of Patients with Diabetes and Cancer: Challenges and Opportunities","volume":"16","author":"Shouman","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2026.108456_bib233","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.diabres.2017.12.010","article-title":"Managing people with diabetes during the cancer palliation in the era of simultaneous care","volume":"143","author":"Ferrari","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"7","key":"10.1016\/j.phrs.2026.108456_bib234","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/dme.13919","article-title":"Challenges in the management of people with diabetes and cancer","volume":"36","author":"Chowdhury","year":"2019","journal-title":"Diabet. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:02:46Z","timestamp":1793692966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826003713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":234,"alternative-id":["S1043661826003713"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108456","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological intersections between type 2 diabetes and cancer: Metabolic crosstalk, antidiabetic therapies and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108456"}}